BCL2L11 and acute lymphoblastic leukemia: The combination of LSD1i with JAK/STAT pathway inhibitor (JAKi, Ruxolitinib) reversed efficiently the expression ratio of BCL2/BIM (anti-/pro-apoptotic) in human and mouse ETP-ALL.